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 Management of Treatment-Associated
Toxicities of Anti-Angiogenic Therapy in
Patients with Brain Tumors
Armstrong TS, et al. Neuro Oncol 2012; 14: 1203–14.
Antiangiogenic therapies have become the most intense area
of clinical research in the treatment of malignant gliomas. In-
troduction of such agents has altered the risks and side effects
of overall glioma treatment, and it is unclear in what way the
addition of antiangiogenic compounds modifies the safety
and tolerability of additional treatment such as radiation or
chemotherapy. In the light of these novel developments, it is
appropriate to review the management of such treatment-as-
sociated toxicities in glioma patients as done in an authoritative
review by Amstrong et al, published in the October issue. Spe-
cifically, the authors address how to deal with hypotension
and proteinuria, wound healing, and the presumably increas-
ed risk of thromboembolic events in patients treated with
antiangiogenic compounds. The authors also provide recom-
mendations for the diagnosis, monitoring, and management
of such complications. Since antiangiogenic compounds will
stay with us in neuro-oncology for some time, this review is
worthwhile to read to be up to date in a field that is gaining
increasing importance in clinical neuro-oncology.
 Glioblastoma Resistance to Anti-VEGF
Therapy Is Associated with Myeloid Cell
Infiltration, Stem Cell Accumulation and
a Mesenchymal Phenotype
Piao Y, et al. Neuro Oncol 2012; 14: 1379–92.
According to a press release by Roche (Basel, Switzerland),
the registration trial for bevacizumab in the treatment of
newly diagnosed glioblastoma, AVAGlio, has reached the pri-
mary endpoint of improving progression-free survival where-
as no mature results for the overall survival endpoint have
been made available yet. These preliminary observations un-
derscore the urgent need to understand pathways of constitu-
tive or acquired resistance to anti-vascular endothelial growth
factor (VEGF) treatments. In the November issue of Neuro-
Oncology, Piao et al from the MD Anderson Cancer Center
analysed the evolution of resistance to anti-VEGF therapy,
using either the VEGF antibody, bevacizumab, or the tyrosine
kinase inhibitor, sunitinib, in the U87MG orthotopic human
glioma model. Bevacizumab doubled survival whereas
sunitinib did not. Sunitinib plus bevacizumab, was superior to
bevacizumab alone. Both agents reduced tumour vascularity,
but bevacizumab was more effective in inhibiting vascularity
in the periphery of the tumours, and revascularization oc-
curred earlier in sunitinib-treated tumours, associated with
tumour progression. Increased numbers of CD11b+/F4/80+
cells were observed earlier in control and sunitinib-treated
animals than in bevacizumab-treated animals and were asso-
ciated with treatment failure. Although only one cell line
model was studied, the study supports the view that a better
understanding of tumour/host cell interactions might help to
improve on the results obtained with angiogenesis inhibition
in the clinic so far.
 EORTC 26083 Phase I/II Trial of Dasatinib
in Combination with CCNU in Patients
with Recurrent Glioblastoma
Franceschi E, et al. Neuro Oncol 2012; 14: 1503–10.
Novel approaches to the treatment of recurrent glioblastoma
are urgently needed. In the December issue, the results of
EORTC trial 26083 were reported. This trial examined the
combination of the Src kinase inhibitor dasatinib and CCNU
in 26 patients with recurrent glioblastoma as the phase-I part
of a planned multicentre, randomized phase-II trial. However,
the randomized part of the trial was not initiated because of
the results of this trial. Five dose levels were explored. Ten
patients experienced dose-limiting toxicity which was mostly
myelosuppression, with rates of grade-3-of-4 neutropenia in
26.9 % and thrombocytopenia in 42.3 %. Median progres-
sion-free survival was only 1.35 months, and only 7.7 % of
the patients were free from progression at 6 months. These
results are inferior compared with historical controls with
CCNU alone; accordingly, EORTC 26083 did not provide any
rationale to move this combination forward in the treatment of
recurrent glioblastoma.
 Survival and Secondary Tumors in Chil-
dren with Medulloblastoma Receiving
Radiotherapy and Adjuvant Chemo-
therapy: Results of Children’s Oncology
Group Trial A9961
Packer RJ, et al. Neuro Oncol 2013; 15: 97–103.
In the January issue, Packer et al reported very interesting re-
sults from Children’s Oncology Group trial A9961 which
compared radiotherapy combined with vincristine plus adju-
vant chemotherapy with platinum, vincristine, and either
CCNU or cyclophosphamide. Patients were enrolled between
December 1996 and December 2000. 379 eligible patients
were analyzed. Five- and 10-year event-free survival rates
were 81 % and 76 %, corresponding results for overall sur-
vival were 87 % and 81 %. The primary site of relapse of the
primary tumour was local. Importantly, 15 patients suffered
secondary neoplasms in the absence of medulloblastoma re-
lapse after a median time of 5.8 years from diagnosis. All sec-
ondary tumours occurred in body regions exposed to radia-
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tion. The high risk of secondary tumours, many of which are
malignant gliomas, is of concern especially with the recent
great advances in the molecular subclassification and more
targeted therapy options for patients with these tumours. It is
of utmost importance to revisit the current standards of care
once novel, more effective agents to treat medullobastoma,
which impact survival, are introduced into clinical practice.
 Survival Meta-Analyses for >1800 Malig-
nant Peripheral Nerve Sheath Tumor Pa-
tients with and without Neurofibroma-
tosis Type 1
Kolberg M, et al. Neuro Oncol 2013; 15: 135–47.
Malignant peripheral nerve sheath tumours (MPNST) are
malignant tumours derived from the peripheral nervous sys-
tem that are notoriously difficult to treat. Surgery and radio-
therapy remain the mainstay of therapy whereas chemo-
therapy is often ineffective. These tumours are strongly asso-
ciated with neurofibromatosis type 1 (NF1). In the February
issue, Kolberg et al performed a metaanalysis of > 1800 pa-
tients with MPNST and reviewed characteristics of 179 pa-
tients from 3 European sarcoma centres in Norway, Sweden,
and Italy. Over time, they found that the traditionally assumed
poorer outcome for MPNST in association with NF1 was not
observed anymore in the last 2 decades possibly because of
more aggressive treatment approaches to MPNST in NF1.
Altogether these observations suggest that MPNST with or
without NF1 may not be intrinsically different tumours and
should be diagnosed, managed, and monitored accordingly.
Of note, the similar outcome with or without NF1 was calcu-
lated for disease-specific survival whereas, overall, there may
still be increased mortality for NF1 patients from other NF1-
associated conditions. This data compilation provides a valu-
able basis for the planning and design of future interventional
studies in NF1 and MPNST.
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